BPG is committed to discovery and dissemination of knowledge
Articles in Press
9/13/2019 10:45:31 PM | Browse: 460 | Download: 393
Category |
Research & Experimental Medicine |
Manuscript Type |
Basic Study |
Article Title |
Ameliorating liver fibrosis in an animal model using the secretome released from miR-122-transfected adipose-derived stem cells
|
Manuscript Source |
Unsolicited Manuscript |
All Author List |
Kee-Hwan Kim, Jae Im Lee, Ok-Hee Kim, Ha-Eun Hong, Bong Jun Kwak, Ho Joong Choi, Joseph Ahn, Tae Yun Lee, Sang Chul Lee and Say-June Kim |
Funding Agency and Grant Number |
Funding Agency |
Grant Number |
National Research Foundation of Korea |
NRF-2015R1D1A1A01060721 |
|
Corresponding Author |
Say-June Kim, MD, PhD, Professor, Surgeon, Department of Surgery, Seoul St. Mary’s Hospital, College of Medicine, the Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul 06591, South Korea. sayjunekim@gmail.com |
Key Words |
Adipose-derived stem cells; Liver fibrosis; MicroRNAs; miR-122; Mesenchymal stem cells; Secretome |
Core Tip |
We herein intended to determine the antifibrotic effects of the secretome released from miR-122-transfected adipose-derived stromal cells (miR-122-secretome). miR122-secrectome and naïve secretome were intravenously administered to the mice with liver fibrosis, respectively. miR122-secrectome infusion provided higher therapeutic potential in terms of reducing collagen content in the liver, inhibiting proinflammatory cytokines, and reducing abnormally elevated liver enzymes than the infusion of the naïve secretome. Proteomic analysis of the miR122-secrectome indicated that the contents of antifibrotic proteins were significantly elevated compared to those in the naïve secretome. Our results demonstrate that miR122-secrectome has higher antifibrotic and anti-inflammatory properties than the naïve secretome. |
Citation |
Kim KH, Lee JI, Kim OH, Hong HE, Kwak BJ, Choi HJ, Ahn J, Lee TY, Lee SC, Kim SJ. Ameliorating liver fibrosis in an animal model using the secretome released from miR-122-transfected adipose-derived stem cells. World J Stem Cells 2019; 11(11):990-1004 |
|
Received |
|
2019-03-12 08:19 |
|
Peer-Review Started |
|
2019-03-15 01:30 |
|
To Make the First Decision |
|
2019-08-06 02:55 |
|
Return for Revision |
|
2019-08-20 02:51 |
|
Revised |
|
2019-09-02 06:49 |
|
Second Decision |
|
2019-09-12 10:04 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2019-09-13 22:45 |
|
Articles in Press |
|
2019-09-13 22:45 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-10-30 01:51 |
ISSN |
1948-0210 (online) |
Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
Website |
http://www.wjgnet.com |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345